Entry Point Capital, LLC Belite Bio, Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
1 transactions
Others Institutions Holding BLTE
# of Institutions
16Shares Held
78.7KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.67 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$1.12 Million0.0% of portfolio
-
Marshall Wace, LLP London, X08.49KShares$704,9320.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$556,5690.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.46KShares$536,6320.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $2.07B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...